Please login to the form below

SCLC

This page shows the latest SCLC news and features for those working in and with pharma, biotech and healthcare.

Can AZ’s Imfinzi challenge Tecentriq in small cell lung cancer?

in previously-untreated patients with extensive-stage SCLC, said to be the most aggressive for of lung cancer. ... SCLC is less common than non-small cell lung cancer (NSCLC) but tends to be more aggressive, growing more quickly and spreading to other

Latest news

Strike three for Rova-T has AbbVie cutting its losses

Approximately two-thirds of patients with SCLC have high levels of DLL3 on the surface of tumours, and the biomarker is thought to be absent from heathy adult tissues. ... MERU compared the ADC to placebo as maintenance therapy following first-line,
AZ’s Imfinzi joins immunotherapy drive in small cell lung cancer

Tecentriq the leader in setting. AstraZeneca’s Imfinzi is the latest PD-1/PD-L1 inhibitor to show clinical activity in small cell lung cancer (SCLC), extending survival when used as ... SCLC is a notoriously hard-to-treat disease that accounts for up
Merck says it has plenty in the pipe beyond Keytruda

cancer (SCLC), and with momentum only just starting to gather in renal cell carcinoma.
Keytruda begins pursuit of rivals in small cell lung cancer

as a third line therapy in SCLC, with Roche’s Tecentriq gaining a prized first line indication in March. ... This study focuses on recently-diagnosed patients with advanced-stage SCLC, which would put it in more direct competition with Tecentriq.
Encouraging early data for Amgen’s BiTE therapies

DLL3) in small-cell lung cancer (SCLC), with data presented on the candidates at ASCO poster sessions.

More from news
Approximately 3 fully matching, plus 21 partially matching documents found.

Latest Intelligence

Deal Watch February 2017

triple-negative breast cancer (TNBC), small-cell lung cancer (SCLC), non-small-cell lung cancer (NSCLC) and pancreatic cancer. .
Deal Watch April 2016

Rova-T showed a 44% overall response rate in DLL-expressing small cell lung cancer (SCLC) patients who had failed one or more standard therapies.
Deal Watch November 2015

July finalised a $730m exclusive deal with Boehringer Ingelheim for HM61713, an orally active third generation EGFR agent in small cell lung cancer (SCLC).

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

OTC / Consumer Health PR Account Director: profit share, pens, life assurance more

Editorial Team Leader – Medical Communications – Buckinghamshire...: Salary TBC

Account Director: Salary TBC

Account Executive: Salary TBC

Scientific Director - Medical Communications - Berkshire: Excellent package on offer

Senior Medical Writer – US Client - Homebased- London: Negotiable

Senior Medical Writer: Salary TBC

Programme Manager / Programme Director – Medical Education - Buc...: Salary TBC

Associate Director – Full Service political / comms consultancy...: Salary TBC

Account Supervisor: Salary TBC

Senior Editor - Medical Communications - South East - Buckingham...: Highly competitive salary &package

Account Director- Macclesfield/ Knutsford/ Oxford: Salary TBC

Medical Writer – Very Flexible Working – Surrey: Negotiable

Account Manager- Knutsford/ Macclesfield/ Oxford: Negotiable

Account Manager, Healthcare Communications: £32, 000 - £40, 000 bonus benefits

Entry Level Editorial Assistant – Medical Education –Buckinghams...: Highly Competitive

Account Director, Medical Education: Salary TBC

Graduate Scientific Editor: DOE

Account Director, Healthcare Communications Agency: £54, 000- £60, 000

Subscribe to our email news alerts

PMHub

Add my company

Creative Medical Research

Specialising in medical device market research and participant recruitment human factors research, our approach is people-centric. We thrive on making...

Latest intelligence

Pharmaceutical innovation in the APAC region: A first-of-its-kind study paints a vivid picture of the APAC region’s future...
Patient journey mapping: exploring the clinical and the emotional journey: By Chris Hodgson, Neil Rees, Sumira Riaz and Karen Petticrew While we can all agree that the value of developing a patient journey map cannot be underestimated when exploring the...
Precision medicine at Blue Latitude Health: At Blue Latitude Health we have identified 90+ insights about commercialising precision medicines. Check out our video to get a run down on three core components of the commercialisation and...